Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence

Progress in Cardiovascular Diseases

Volumn 44, Issue 2, 2001, Pages 121-152

  Slavik, Richard S ^a   Tisdale, James E ^a   Borzak, Steven ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; FLECAINIDE; IBUTILIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE;

CARDIOVERSION; DISEASE DURATION; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; REVIEW; SINUS RHYTHM; TREATMENT PLANNING;

EID: 0034837672     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2001.26966     Document Type: Article

References (130)

1. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates
2. Epidemiology and natural history of atrial fibrillation: Clinical implications
3. Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study
4. Epidemiologic features of chronic atrial fibrillation: The Framingham study
5. Management of supraventricular tachycardia in the emergency department
6. Hospitalization for arrhythmias in the United States: Importance of atrial fibrillation
7. Supraventricular arrhythmia in patients having non-cardiac surgery: Clinical correlates and effect on length of stay
8. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association
9. Atrial fibrillation: Current knowledge and recommendations for management
10. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care
11. Cost-effective management of acute atrial fibrillation: Role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy
12. Relation between echocardiographically determined left atrial size and atrial fibrillation
13. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter
14. The changes in cardiac output with reversion of atrial fibrillation to sinus rhythm
15. Left ventricular function in patients with atrial fibrillation before and after cardioversion
16. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease
17. Functional capacity before and after fibrillation: A controlled study
18. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for reversion of new-onset atrial fibrillation
19. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation
20. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: Evidence for "atrial stunning" as a mechanism of thromboembolic complications
21. Clinical variables affecting recovery of left atrial mechanical function after cardioversion from atrial fibrillation
22. Clinical and echocardiographic features influencing recovery of atrial function after cardioversion of atrial fibrillation
23. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: Observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT)
24. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design
25. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats
26. Electrophysiologic mechanisms of perpetuation of atrial fibrillation
27. Mechanisms of atrial fibrillation and action of drugs used in its management
28. Effect of atrial fibrillation on atrial refractoriness in humans
29. Electrical remodeling of the human atria: Similar effects in patients with chronic atrial fibrillation and atrial flutter
30. Atrial enlargement as a consequence of atrial fibrillation: A prospective echocardiographic study
31. Atrial fibrillation
32. Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans
33. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal sinus rhythm
34. Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter
35. Efficacy and cost analysis of ibutilide
36. Risks of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
37. The periodic health examination
38. Rules of evidence and clinical recommendations on the use of antithrombotic agents
39. Clinical recommendations using levels of evidence for antithrombotic agents
40. Grades of recommendation for antithrombotic agents
41. Early and late results of conversion of atrial fibrillation with quinidine: A clinical and hemodynamic study
42. Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment
43. Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment
44. Combined administration of propranolol and quinidine in the conversion of paroxysmal atrial fibrillation
45. Flecainide versus quinidine for the conversion of atrial fibrillation to sinus rhythm
46. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up
47. Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm
48. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine
49. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation
50. Amiodarone versus quinidine for conversion of recent onset atrial fibrillation to sinus rhythm
51. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol-digoxin-quinidine trial)
52. Maintenance of sinus rhythm after DC reversion of atrial fibrillation: A double-blind controlled trial of long-acting quinidine bisulphate
53. Comparative efficacy of quinidine and verapamil in the maintenance of sinus rhythm after DC conversion of atrial fibrillation: A controlled clinical trial
54. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm
55. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: A prospective parallel placebo-controlled multicentre study
56. Effects of oral disopyramide on acute-onset atrial fibrillation with concurrent monitoring of serum drug concentration
57. Conversion of acute atrial fibrillation with procainamide
58. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: Relation to left atrial size
59. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion
60. Procainamide infusion and acute atrial fibrillation
61. Management of atrial tachyarrhythmias in the critically ill: A comparison of intravenous procainamide and amiodarone
62. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation
63. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
64. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm
65. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion
66. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm
67. Acute conversion of atrial fibrillation to sinus rhythm: Clinical efficacy of flecainide acetate. Comparison of two regimens
68. Clinical efficacy of flecainide acetate in atrial fibrillation
69. Randomized double blind trial of oral versus intravenous flecainide for cardioversion of acute atrial fibrillation
70. Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide
71. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with systemic hypertension
72. Conversion of recent-onset atrial fibrillation to sinus rhythm: Effects of different drug protocols
73. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation
74. Must antidysrhythmic agents be given to all patients with new-onset atrial fibrillation?
75. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs
76. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation
77. Clinical course of recent-onset atrial fibrillation treated with oral propafenone
78. Propafenone for conversion of recent-onset atrial fibrillation: A controlled comparison between oral loading dose and intravenous administration
79. Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: Is in-hospital admission absolutely necessary?
80. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease: A randomized, controlled trial
81. Value of a single oral loading dose of propafenone in converting recent-onset atrial fibrillation: Results of a randomized, double-blind, controlled study
82. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: Comparison of two regimens
83. Randomized, crossover, controlled comparison of oral loading versus intravenous infusion of propafenone in recent-onset atrial fibrillation
84. Amiodarone versus propafenone for conversion of chronic atrial fibrillation: Results of a randomized, controlled study
85. Cardioversion with sotalol in selected patients with vagally and adrenergically mediated paroxysmal atrial fibrillation
86. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation
87. Intravenous amiodarone for therapy of atrial fibrillation and flutter in critically ill patients with severely depressed left ventricular function
88. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias
89. Efficacy of iv amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients
90. Hemodynamic responses to amiodarone in critically-ill patients receiving catecholamine infusions
91. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias
92. Intravenous amiodarone in the acute termination of supraventricular arrhythmias
93. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response
94. Efficacy and safety of intravenous amiodarone in recent-onset atrial fibrillation: Experience in patients admitted to a general internal medicine department
95. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias
96. A comparison of cardioversion of atrialfibrillation using oral amiodarone, intravenous amiodarone and dc cardioversion
97. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias
98. A clinical study of amiodarone as a single oral dose in patients with recent-onset atrial tachycardia
99. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: A prospective, randomized study
100. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
101. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm
102. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected myocardial infarction
103. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation
104. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study
105. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: A randomized, digoxin-controlled study
106. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: The effect of no treatment and high-dose amiodarone-A randomized, placebo-controlled study
107. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: A placebo-controlled study
108. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation
109. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter: A multicentre, randomized, double-blind, placebo-controlled study
110. Efficacy of amiodarone for the termination of persistent atrial fibrillation
111. Amiodarone for the conversion of established atrial fibrillation and flutter
112. Conversion of atrial fibrillation to sinus rhythm with amiodarone
113. Amiodarone in the management of refractory atrial fibrillation
114. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone
115. Rapid control of atrial tachyarrhythmias with high-dose oral amiodarone
116. Suppression of arrhythmias within hours after a single oral dose of amiodarone and relation to plasma and myocardial concentrations
117. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation
118. Termination of recent-onset atrial fibrillation/flutter in the emergency department: A sequential approach with intravenous ibutilide and external cardioversion
119. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy
120. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation
121. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: A dose-response study
122. Effiacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation
123. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation
124. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
125. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study
126. Acute treatment of atrial fibrillation: Spontaneous conversion rates and cost of care
127. Likelihood of conversion of atrial fibrillation to sinus rhythm
128. Intravenous amiodarone versus propafenone for atrial fibrillation and flutter after cardiac surgery: A note of caution
129. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter
130. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment